



## **French marketing authorization approval for Levidcen**

**Nîmes, 23 April 2015** – Advicenne, a late-stage biopharmaceutical company focused on the development of paediatric friendly therapeutics for the treatment of orphan renal and neurological diseases announces that the Company has received the French marketing authorization approval for Levidcen, coated granules of levetiracetam Levidcen® has been approved by the French Agency on October 20th 2014.

Levidcen is available in sachets with 4 different dosages of coated granules of levetiracetam: 250mg, 500mg, 750mg and 1 000mg Levetiracetam coated granules have been developed by the German company Desitin. The specialty is currently marketed in Germany, UK, Spain, Portugal, Switzerland, Norway and Sweden and is indicated for the treatment of epilepsy

###

### **For further information, please contact:**

#### **Advicenne**

LA Granier, S Delbaere, J Rachline

[info@advicenne.com](mailto:info@advicenne.com)

+33 (0)4 66 05 54 20

#### **About Advicenne**

Advicenne is a late-stage biopharmaceutical company focusing on the development of paediatric friendly therapeutics for the treatment of orphan renal and neurological diseases. The Company has a strong portfolio of products in late-stage development targeting critical unmet needs in nephrology and neurology. Advicenne also develops a clinical and pre-clinical pipeline of potential treatments for additional orphan diseases in collaboration with Key Opinion Leaders.

The Company was established in 2007 in Nimes (France). Since its inception, the Company has raised close to €30 million in equity from leading venture capital investors Innobio (Bpifrance), IXO Private Equity, IRDI SORIDEC Gestion, Cemag Invest and MI Care.